Indian Pharmaceutical Industry The Indian pharmaceutical industry has seen tremendous growth in the last decades and is one of the fastest growing pharmaceutical markets in the world. It is the fourth largest pharmaceutical market in the Asia Pacific region behind Japan, China and South Korea. However, the per capita spending of US$12 is among the lowest in the world, similar to levels in Pakistan and Vietnam. .India accounts for almost 10% of the global market by volume and is rapidly emerging
Words: 257 - Pages: 2
7/1/2011 Contents Introduction 2 What is clinical research? 2 The state of health in India 2 Clinical Research Market in India 3 Factors that Continue to Make India Attractive for Future Clinical Trial Outsourcing: 4 Challenges for the Indian Clinical Research Industry 6 Cinical research profession 7 Conclusion 8 Introduction Successful persons in business are noted to be blessed with innovation, perseverance and a broad vision. Its critical to have the “big picture”
Words: 2376 - Pages: 10
Pharmaceutical Testing of India's People Maira Watts Tarleton State University Abstract This paper looks at the pharmaceutical medical trials and clinical drug testing on the people of India as the ethical perspective conducted from journals and articles provided along with a video that was shown to understand the perspective of what we were to analyze. The journals speak on the process of approval, laws that are in place to advocate for the people, and the overall plight of the subjects
Words: 1557 - Pages: 7
University Institute of Management Kengri Campus Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, GSK is a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs. 2699 crore and a share of 4.2%. The GSK India product portfolio includes prescription medicines and vaccines. Our prescription
Words: 3823 - Pages: 16
CASE 6.3 ELLY LILLI IN INDIA: RETHINKING THE JOIN VENTURE STRATEGY Summary: The case consists of two major pharmaceutical companies that joint to collaborate their research and pharmaceutical technologies to start a joint venture in India. Both have valuable resources that have benefited both companies during the joint venture. Now both are questioning if there is still any value in maintaining the joint venture in India and will be deciding what will be the best route to take. Ranbaxy Laboratories
Words: 1152 - Pages: 5
consequential, special, incidental or punitive damages to any person or entity for any matter relating to this report even if advised of the possibility of such damages. The member firms of the PricewaterhouseCoopers network (www.pwc. com) provide industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 140,000 people in 149 countries share their thinking, experience and solutions to develop fresh perspectives and
Words: 6564 - Pages: 27
of evergreening enables protection of a drugs patent beyond its initial term despite only small, trivial changes to the invention itself. However, what these critics fail to recognize are the benefits of incremental innovations within the pharmaceutical industry. These incremental innovations can produce a reformulated medicine to encourage children’s compliance (more tolerable drug forms), increase a drugs heat-stability so it can be effective in many environments across the globe or even increase
Words: 884 - Pages: 4
Eli Lilly in India: Rethinking the Joint Venture Strategy To: Dr. Lorenzo Tallarigo, President of Intercontinental Operations From: Senior Operations Director Re: Strategic direction for joint venture between Eli Lilly Co and Ranbaxy Laboratories Limited Problem After enjoying a successful JV partnership with Ranbaxy for the last few years, the strategic decision that Lilly now has to make is how to move forward. The Indian pharmaceutical industry has witnessed some significant changes and
Words: 1871 - Pages: 8
Pharmaceutical and Medical Products Practice India Pharma 2020 Propelling access and acceptance, realising true potential The report is furnished to the recipient for information purposes only. Each recipient should conduct its own investigation and analysis of any such information contained in this report. No recipient is entitled to rely on the work of McKinsey & Company, Inc. contained in this report for any purpose. McKinsey & Company, Inc. makes no representations or warranties regarding
Words: 9542 - Pages: 39
and today, it is one of the most established companies in the Indian and Global pharmaceutical industry. DRL is a 200 million dollar venture with presence in almost all major therapeutic areas, providing affordable and innovative medicines in all major therapeutic areas like gastro-intestinal, oncology, pain management, cardiovascular, dermatology, diabetes, etc. DRL operates in three business segments- Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products. Its
Words: 4430 - Pages: 18
